<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We identified 382 consecutive patients with lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> associated with serum monoclonal IgM paraprotein and classified each <z:hpo ids='HP_0002664'>neoplasm</z:hpo> according to World Health Organization criteria </plain></SENT>
<SENT sid="1" pm="."><plain>Lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenstr√∂m macroglobulinemia</z:e> (LPL/WM) was most common, 225 cases (median serum IgM level, 2.2 g/dL; range, 0.2-10.9 g/dL) </plain></SENT>
<SENT sid="2" pm="."><plain>For 157 cases, classification and median (and range in g/dL) IgM levels were as follows: <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e>; n = 77), 0.9 (0.1-2.1); marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 27), 0.5 (0.1-2.4); follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 18), 0.4 (0.1-1.6); mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 11), 0.4 (0.2-1.3); diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>; n = 7), 0.5 (0.2-1.0); <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> associated with low-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 5), 0.9 (0.4-3.0); angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 4), 0.8 (0.8); and CD5+CD23- low-grade B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassified (n = 8), 0.5 (0.3-2.9) </plain></SENT>
<SENT sid="3" pm="."><plain>The results show IgM <z:e sem="disease" ids="C0030489" disease_type="Disease or Syndrome" abbrv="">paraproteinemia</z:e> was associated most commonly with LPL/WM (58.9%), followed by <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e> (20.2%) </plain></SENT>
<SENT sid="4" pm="."><plain>Although serum IgM levels greater than 3 g/dL were restricted to patients with LPL/WM, most patients with LPL/WM had paraprotein levels less than 3 g/dL </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, serum IgM paraprotein level is not a reliable discriminator in differential diagnosis </plain></SENT>
</text></document>